News &amp; Updates

Wearing of face shields proves golden as a preventive measure, reducing not only the number of SARS-CoV-2 infections but also that of hospital-acquired infections among healthcare personnel, as shown in a study reported at the 2020 virtual IDWeek meeting.

Face shield minimizes spread of SARS-CoV-2, hospital-acquired infections

Brodalumab safe, effective in hidradenitis suppurativa

Treatment with subcutaneous brodalumab is well tolerated in patients with hidradenitis suppurativa (HS), showing improvement in clinical outcomes and no serious adverse events, according to a recent study.

Brodalumab safe, effective in hidradenitis suppurativa

Tocilizumab may reduce mortality in COVID-19 patients at risk of CRS

Tocilizumab (TCZ) therapy appears to be effective in patients at risk of cytokine release syndrome (CRS) from the novel coronavirus disease (COVID-19), suggests a study presented at ID Week 2020. Those receiving TCZ in a nonintensive care unit (non-ICU) setting show better response than ICU patients.

Tocilizumab may reduce mortality in COVID-19 patients at risk of CRS

Corticosteroids show promise in paediatric DRESS

Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.

Corticosteroids show promise in paediatric DRESS

Prescription EPA benefits statin-treated patients with history of PCI

A daily, 4-gram dose of icosapent ethyl (IPE) led to a significant reduction in ischaemic events in a subgroup of patients from the REDUCE-IT* cohort who had prior PCI**, according to the prespecified analysis of the REDUCE-IT PCI trial presented at TCT 2020.

Prescription EPA benefits statin-treated patients with history of PCI

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of nonsmall cell lung cancer (NSCLC) commonly triggers cutaneous side effects, which often leads to drug reductions or discontinuation, reports a new study at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).

Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC

Pancreatic cancer incidence and mortality on the rise globally

The incidence and mortality of pancreatic cancer are on the rise globally, particularly among women and individuals ≥50 years of age, but an increasing trend is also found in younger individuals in some countries.

Pancreatic cancer incidence and mortality on the rise globally

Autologous fat transfer promising for scar conditions, fibrosis

Autologous fat transfer holds good potential for the treatment of fibrosis and scar-related problems, reports a recent meta-analysis.

Autologous fat transfer promising for scar conditions, fibrosis

Asymptomatic COVID-19 cases carry as much virus as those with symptoms

08 Nov 2020 by

Up to one-fifth of individuals with COVID-19 are asymptomatic, with many of them harbouring as much coronavirus as patients who are symptomatic, a study shows — raising concerns that asymptomatic carriers may drive community spread of COVID-19.

Asymptomatic COVID-19 cases carry as much virus as those with symptoms

Acarbose confers hepato-, cardioprotection in T2D patients with end-stage renal disease

Acarbose may be safely used in type 2 diabetes (T2D) patients with comorbid renal diseases, with real-world data showing that the glucose-lowering drug reduces the risks of hepatic injury, cardiovascular diseases, and all-cause mortality.

Acarbose confers hepato-, cardioprotection in T2D patients with end-stage renal disease